Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The DTU is collaborating with the University of Cambridge on a new randomised control trial for people with cystic fibrosis related diabetes (CFRD). The trial has started to enroll participants with CFRD, a common comorbidity in cystic fibrosis (CF), affecting 15-20% of adolescents and 30-50% of adults. The recommended management is insulin therapy by multiple daily injections, which adds significantly to the burden of self-managing CF.

Closed-loop insulin delivery systems include an algorithm that responds to real-time glucose levels from a sensor continuously measuring interstitial glucose beneath the skin; the system then automatically adjusts insulin doses delivered through an insulin pump. CL4P-CF (Closed-Loop For People living with Cystic Fibrosis) is NIHR-funded, multi-centre, and 6 months long and aims to find out if a hybrid closed-loop system  - compared with standard insulin treatment plus a glucose sensor  - can improve control of blood glucose and quality of life in young people and adults with CFRD.